News

23 01, 2018

New study shows that some cases of aggressive prostate cancer may be linked to high-fat diet

2018-01-23T09:50:13+00:00January 23rd, 2018|

Dr. Michael Lazar of California HIFU shares insights from a new study on prostate cancer, emphasizing that a healthy diet may contribute to prevention of the disease. There have been many discoveries recently that identify a link between a diet rich in fatty foods and increased risk of prostate cancer. The evidence continues to mount with the results of this new study investigating the effects of high-fat diets on certain prostate cancer tumors. Researchers at the Cancer Center at Beth Israel Deaconess Medical Center (BIDMC) discovered genetic mechanisms that promote cancer tumor metastasis, pointing to the typical Western high-fat diet as a key factor in driving that metastasis. The study was published this week in two journals; Nature Genetic and Nature Communications. It compared [...]

16 01, 2018

New genetic tool predicts age for onset of aggressive prostate cancer

2018-01-16T14:30:43+00:00January 16th, 2018|

Researchers developed genetic tool for predicting onset of aggressive prostate cancer An international team, led by researchers at the University of California San Diego School of Medicine, has developed and validated a genetic tool for predicting age of onset of aggressive prostate cancer, a disease that kills more than 26,000 American men annually. The tool, described in the January 11 online issue of the BMJ(formerly the British Medical Journal), may potentially be used to help guide decisions about who to screen for prostate cancer and at what age. Currently, detection of prostate cancer relies primarily upon the prostate-specific antigen (PSA) screening blood test. But PSA testing is not very good as a screening tool. While it reduces deaths from prostate cancer, indiscriminate PSA screening also [...]

9 01, 2018

New roadmap developed to genetically test for hereditary prostate cancer

2018-01-09T08:50:54+00:00January 9th, 2018|

A roadmap to help identify which men and their families may benefit from genetic evaluation for inherited prostate cancer has been developed by a team of researchers. To date, there have been few recommendations to guide physicians about when to offer men genetic consultation for prostate cancer risk. Now, an international and inter-specialty panel of experts convened at the Sidney Kimmel Cancer Center (SKCC) at Thomas Jefferson University have developed a comprehensive set of recommendations. This consensus statement, published December 13th in the Journal of Clinical Oncology, will help physicians and stakeholders make sense of a rapidly evolving field of practice. "There is increasing recognition that some prostate cancers can be inherited. Genetic testing could provide men and their families with information about cancer [...]

2 01, 2018

#1 New Year’s Resolution for Men: Get screened for prostate cancer

2018-01-02T13:01:35+00:00January 2nd, 2018|

#1 New Year’s Resolution for Men: Get screened for prostate cancer   Santa Rosa urologist and prostate cancer expert Dr. Michael Lazar provides an overview of prostate cancer screening options; says early detection saves lives. “Knowing the many options for treating prostate cancer is something all men at risk of developing the disease need to be informed about,” says Dr. Lazar. “Most men know about the unpleasant side effects that go along with traditional models of prostate cancer treatment, including urinary incontinence, bowel and erectile dysfunction. But some of the newer treatment modalities such as HIFU (high-intensity focused ultrasound) can only be undertaken at the early stages, when damage to surrounding tissue can best be mitigated, and most side effects eliminated.” Why Early [...]

14 11, 2017

CMS Announces Increase To ASC Payment For HIFU Prostate Ablation

2017-12-13T13:37:18+00:00November 14th, 2017|

SonaCare Medical Reports That Medicare recognizes HIFU prostate ablation as a device-intensive procedure driving new ASC payment going into effect on or after October 1, 2017 CHARLOTTE, N.C., Sept. 20, 2017 SonaCare Medical, leading developer and manufacturer of high intensity focused ultrasound (HIFU) technologies, is pleased to announce an increase in Medicare payment for prostate HIFU ablation in the Ambulatory Surgical Center (ASC) setting. In the October 2017 update of the ASC Payment System, the Centers for Medicare and Medicaid Services (CMS) indicated that the ASC payment status for C9747, the code used to bill for HIFU ablation of prostate tissue, now recognizes HIFU as a "device-intensive procedure". The new typical ASC payment level is $5,444.89, as compared to the approximately $4,000 payment amount which went [...]

8 11, 2017

Research News: Reduced Risk of Prostate Cancer in Men with Low Testosterone

2017-12-13T13:37:18+00:00November 8th, 2017|

Men with unusually low amounts of testosterone in their blood are around 20% less likely to develop prostate cancer, according to new research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool. Scientists from the University of Oxford conducted the largest analysis of hormones and prostate cancer risk to date. The study – funded by Cancer Research UK – looked at blood samples from around 19,000 men aged 34-76 years, collected between 1959 and 2004. Of these men 6,900 went on to develop prostate cancer. The researchers divided the 19,000 men into ten groups – ranging from men with the lowest amount of testosterone in their blood to those with the highest, and compared their prostate cancer risk. They found that men [...]

23 10, 2017

New study reveals: Regret is lasting for many men who undergo traditional prostate cancer treatments

2017-12-13T13:37:18+00:00October 23rd, 2017|

Responding to a recent review of patient comments spanning two decades Dr. Michael Lazar of California HIFU talks about the importance of informing prostate cancer patients about all available treatment options. A recent study revealed this month that as they get older, some men who have undergone treatment for prostate cancer come to regret the treatment decisions they made. This study reviewed the survey results of 934 men conducted at intervals of one, two, five, and 15 years after they were treated for prostate cancer. Most of the men (89%) were treated with surgery or radiation. Ultimately, 14.6% of the entire group expressed some regret over treatment results (16.6% of the radiation-treated men, 15% of the surgically-treated men, and 8.2% of the men treated conservatively). [...]

17 10, 2017

New research could lead to reduction in recurrence of prostate cancer

2017-12-13T13:37:18+00:00October 17th, 2017|

Recurrence of prostate cancer could be reduced thanks to exciting new discovery Ground breaking research could reduce the recurrence of prostate cancer in males, a new study in the journal Nature Communications reports. During this in depth study, an international team of researchers led by British scientists investigated the impact of anti-hormone therapy on samples taken from patients with prostate cancer. Anti-hormone therapy is a commonly prescribed treatment for cancer of the prostate, which helps to reduce the levels of male hormones -- that stimulate cancer cells to grow -- in the gland. Researchers discovered that an inadvertent consequence of anti-hormone therapy treatment is the activation of the DNA repair enzyme, PARP. The triggering of PARP enables cancer cells to withstand anti-hormone therapy treatment, causing [...]

11 10, 2017

Prostate Cancer News: PSA screening significantly reduces the risk for death

2017-12-13T13:37:19+00:00October 11th, 2017|

After differences in implementation and settings were accounted for, two important prostate cancer screening trials provide compatible evidence that screening reduces prostate cancer mortality. After differences in implementation and settings were accounted for, two important prostate cancer screening trials provide compatible evidence that screening reduces prostate cancer mortality. These findings suggest that current guidelines recommending against routine PSA-based screening may be revised. However, questions remain about how to implement screening so that the benefits outweigh the potential harms of over-diagnosis and overtreatment. The findings are published in Annals of Internal Medicine. Current guidelines from the United States Preventive Services Task Force (USPSTF) recommend against prostate-specific antigen (PSA) screening for prostate cancer because the evidence for the test showed very low probability that it would reduce [...]